RxDoctor Payments Data

Holly Goracke

Family Medicine · Oklahoma City, OKNPI 1659695450

Payments from drug & device makers

$5,151in general payments, 2019–2025

Across 303 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$619
  • Lilly USA, LLC$531
  • Novo Nordisk$463
  • GSK$429
  • Otsuka America Pharmaceutical, Inc.$415
  • AstraZeneca$328
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,151100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,151 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$123,602
Medicare patients
170
Services billed
3,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide54$69,555
JardianceEmpagliflozin38$41,840
OzempicSemaglutide20$21,360
FarxigaDapagliflozin Propanediol18$18,868
MyrbetriqMirabegron28$18,549
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$17,727
EliquisApixaban19$14,559
GlyxambiEmpagliflozin/Linagliptin15$13,693
JanuviaSitagliptin Phosphate15$12,821
TrulicityDulaglutide13$12,376
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$11,156
Rasagiline Mesylate12$2,702
Venlafaxine Hcl ErVenlafaxine Hcl28$2,441
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,383
Levothyroxine Sodium205$1,852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$531$81,93067 claims
Boehringer IngelheimJardiance, Glyxambi, Stiolto Respimat$172$66,69069 claims
Novo NordiskOzempic$463$21,36020 claims
AstraZenecaFarxiga$328$18,86818 claims
Astellas Pharma US IncMyrbetriq$110$18,54928 claims
GSKTrelegy Ellipta$429$17,72720 claims
PfizerEliquis$298$14,55919 claims
MerckJanuvia$86$12,82115 claims
AbbVieSynthroid$619$65115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →